Clinical trial
A Study of NX-1607 in Adults With Advanced Malignancies
NCT05107674
Study timeline
Study start (actual)2021-09-29Date precision: day
Registry last updated2025-09-09
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Ovarian Cancer, Epithelialunresolved
Gastric Cancerunresolved
GastroEsophageal Junction (GEJ) Cancerunresolved
Head and Neck Squamous Cell Carcinomaunresolved
Metastatic or Unresectable Melanomaunresolved
Non-small Cell Lung Cancer (NSCLC)unresolved
Malignant Pleural Mesothelioma (MPM)unresolved
Triple Negative Breast Cancer (TNBC)unresolved
Metastatic Urothelial Carcinomaunresolved
Cervical Cancerunresolved
Diffuse Large B Cell Lymphoma (DLBCL)unresolved
Richter Transformationunresolved
Interventions
NX-1607DRUG
PaclitaxelDRUG · verified · RxNorm: paclitaxel
Sponsors & collaborators
Nurix Therapeutics, Inc.lead sponsor
Mapped research locations
HoustonTexas, United States1ChicagoIllinois, United States1Los AngelesCalifornia, United States1San FranciscoCalifornia, United States1LondonUnited Kingdom1SeattleWashington, United States1AuroraColorado, United States1Oklahoma CityOklahoma, United States1Chapel HillNorth Carolina, United States1ManchesterUnited Kingdom1CharlottesvilleVirginia, United States1DuarteCalifornia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05107674 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.